Get the Latest Catalent Stock Quote and Insights

To get the latest Catalent stock quote, you can check the NASDAQ website, where it's listed under the ticker symbol CTLT.

Catalent's stock has shown significant growth over the years, with a market capitalization of over $10 billion.

As of the latest report, the company's stock price has been steadily increasing, with a current market price of around $50 per share.

If you're interested in staying up-to-date on Catalent's stock performance, you can also consider following financial news outlets or setting up stock alerts.

The acquisition of Catalent by Novo Holdings is a significant development in the life sciences industry.

Novo Holdings completed its acquisition of Catalent in an all-cash transaction valued at approximately $16.5 billion. This was a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024.

Catalent shareholders will receive $63.50 per share. Following the acquisition, Catalent will operate as a private company, with Alessandro Maselli continuing as President and CEO.

Novo Nordisk will acquire three fill-finish sites from Novo Holdings, located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium. Catalent's common stock will be delisted from the New York Stock Exchange.

The regulatory closing conditions for the transaction have been fulfilled. This includes the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States.

Here's a summary of the key regulatory updates:

The acquisition is expected to close towards the end of 2024, subject to regulatory approvals.

Catalent's revenue in 2024 was $4.38 billion, a 2.77% increase from the previous year.

The company posted a loss of -$1.04 billion in 2024, a significant increase of 307.4% compared to the previous year.

Catalent missed Wall Street estimates for first-quarter revenue, with a surprise loss posted in 2024.

The company's fourth-quarter revenue, however, beat analysts' estimates, with a boost from its biologics segment that develops and manufactures cell and gene therapies.

Catalent's financial performance was likely influenced by its acquisition deal with Novo Holdings, which was close to being finalized in 2024.

Catalent stock has been the subject of various analyst recommendations and forecasts. The average rating for CTLT stock is "Hold" according to 6 analysts.

Analysts have been actively updating their recommendations on Catalent stock. For example, Baird Downgraded Catalent to Neutral From Outperform, with a price target of $63.50.

Barclays has been closely following Catalent stock, raising its price target to $63 from $47 and maintaining an Equalweight Rating. This suggests that the analyst expects the stock to perform moderately well.

Another analyst, Argus, Downgraded Catalent to Sell From Buy, indicating a more bearish outlook. This change in recommendation may be a result of the analyst's reassessment of the company's performance.

Here are the key analyst recommendations and price targets for Catalent stock:

The 12-month stock price forecast for CTLT stock is $63.4, which represents a decrease of -0.13% from the latest price.

Catalent is a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, cell and gene therapies, and consumer health products.

The company was founded in 1903 and has a long history of innovation in the pharmaceutical industry.

Catalent's headquarters is located in Somerset, New Jersey, USA, and it has operations in over 30 countries worldwide.

Catalent has a diverse portfolio of products and services, including softgels, capsules, tablets, and oral films.

The company has a strong focus on research and development, with a dedicated team of scientists and engineers working to develop new technologies and solutions.

Catalent has a long-standing commitment to quality and regulatory compliance, with a robust quality management system in place.

The company has a strong track record of delivering innovative solutions to its customers, with a reputation for excellence in the industry.

Catalent, Inc. was dropped from several indices, including the S&P 500 Value, S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index, and the S&P 500 Equal Weighted, among others, on December 22.

Catalent, Inc. was also dropped from the S&P Global 1200, S&P 500 Health Care, and FTSE All-World Index on December 22 and 19, respectively.

Here are some key dates related to the changes in Catalent's indices:

Catalent, Inc. was acquired by Novo Holdings, with the acquisition cleared to close on December 16. The acquisition was completed on December 18.

Catalent's dividend calendar is a bit of a mystery, as it appears to be a blank slate. The company has not paid a dividend in any of the years listed in the calendar.

Looking at the calendar, we can see that Catalent Inc has not paid a dividend in any of the years from 2024 to 2010. This is a stark contrast to other companies in the same industry.

Here is a breakdown of the dividend calendar for Catalent Inc:

Catalent, Inc. has been in the news recently, and one of the ways to stay informed is through press releases. Catalent : Novo Holdings Completes Acquisition of Catalent Form 8 K was announced on Dec. 18.

The acquisition was completed by Novo Holdings, and it was cleared to close on Dec. 16. This is according to the press release Novo Nordisk A/S, The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close.

Catalent and Novo Holdings have fulfilled all regulatory closing conditions for the pending transaction. This is stated in the press release Catalent : and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction Form 8 K, also dated Dec. 16.

Here are the key dates related to the acquisition:

These press releases provide valuable information about the acquisition and its status.

Catalent's stock quote can be accessed through various online platforms, including Yahoo Finance and Google Finance.

Catalent's stock symbol is CTLT.

You can view Catalent's stock chart to track its performance over time, including daily, weekly, and monthly fluctuations.

Let's dive into the key data for this stock, and I'll highlight some important facts from the table.

The sales per share have been steadily increasing, with a notable jump from $20.31 in 2020 to $24.20 in 2024.

Looking at the P/E ratio, we can see that it has been relatively consistent over the past few years, ranging from 34.75 to 37.97.

The equity ratio has been on a downward trend, dropping from 45.64% in 2022 to 36.95% in 2024.

Here's a summary of the key data:

The debt ratio has been increasing, with a notable jump from 53.09% in 2021 to 63.05% in 2024.

A chart is a visual representation of stock performance over time, helping investors make informed decisions.

It typically includes essential data such as the stock's opening, high, low, and closing prices, making it easy to track its fluctuations.

The chart can also display the stock's volume, indicating the number of shares traded during a given period.

This information can be especially useful for identifying trends and patterns in the stock's performance.

The chart's scale can be adjusted to display a specific time frame, from a few minutes to several years, allowing investors to analyze the stock's performance over different periods.

Catalent and Novo Holdings have received unconditional approval from the European Commission for their pending acquisition transaction. This approval is a significant milestone in the transaction's progress.

The deal is expected to close towards the end of 2024, subject to remaining regulatory clearances and customary closing conditions. Catalent's stockholders have already approved the transaction with a 99.2% approval rate.

Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. The transaction is not contingent on financing.

The EU antitrust approval was granted after regulators said they did not see any competition issues. This approval was a key condition for the transaction to move forward.

All regulatory closing conditions for the transaction have been fulfilled, with closure expected in the coming days. This means that the transition to private ownership under Novo Holdings is now imminent.

The transaction is expected to bring benefits to Catalent, including additional resources and support to drive innovation and enhance offerings for customers and patients.